Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects
A study in subjects with a type of B cell lymphoma (DLBCL)to evaluate the response rate, efficacy, safety and tolerability of YM155
Lymphoma, Large-Cell, Diffuse|Lymphoma, B-Cell Refractory
DRUG: YM155
Overall response rate, 15 treatment cycles
Safety, efficacy, pharmacokinetics, and tolerability, 15 treatment cycles
1 arm (Active), Phase 2 Study to evaluate response rate, efficacy, safety and tolerability of YM155